Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 8.4% during the 4th quarter, Holdings Channel reports. The firm owned 153,835 shares of the biopharmaceutical company’s stock after selling 14,180 shares during the period. Motley Fool Wealth Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $6,425,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Victory Capital Management Inc. lifted its holdings in Ultragenyx Pharmaceutical by 8.8% during the 3rd quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company’s stock worth $608,000 after buying an additional 884 shares in the last quarter. Mutual of America Capital Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at $321,000. Swiss National Bank raised its stake in shares of Ultragenyx Pharmaceutical by 9.1% in the third quarter. Swiss National Bank now owns 159,152 shares of the biopharmaceutical company’s stock valued at $8,841,000 after acquiring an additional 13,300 shares in the last quarter. Quest Partners LLC purchased a new position in Ultragenyx Pharmaceutical in the third quarter valued at $119,000. Finally, Massachusetts Financial Services Co. MA grew its stake in Ultragenyx Pharmaceutical by 46.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 542,373 shares of the biopharmaceutical company’s stock worth $30,129,000 after purchasing an additional 172,126 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This represents a 0.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 136,370 shares of company stock valued at $5,751,499. Insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on RARE. Canaccord Genuity Group lifted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Wedbush restated a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Finally, Wells Fargo & Company boosted their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.71.

Ultragenyx Pharmaceutical Stock Down 1.7 %

RARE opened at $38.69 on Wednesday. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -6.10 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The business’s 50 day moving average is $41.78 and its two-hundred day moving average is $47.15.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.